CDH1 and mesothelioma: A recent study on the pharmacological effects of FAK inhibitors has demonstrated a significant correlation between E-cadherin mRNA levels and VS-4718 in merlin-negative mesothelioma [15], suggesting that E-cadherin may serve as a promising biomarker for predicting the response to FAK inhibitors in mesothelioma, which should be tested in clinical settings.